Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Phase III Compazine vs Methadone vs Tetrahydrocannabinol vs Placebo in Patients Receiving ADR for Malignant Neoplasms

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care				Completed				no age specified								MAYO-818304 NCCTG-818304, NCI-W82-1092, W82-1092

Last Modified: 5/23/2007


2.		Phase III Randomized, Double-Blind Study of Megestrol vs Dronabinol vs Both in Patients with Cancer-Related Anorexia and Cachexia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				NCI				NCCTG-959255 NCI-P96-0075


3.		Phase III Antiemetic Therapy with Intramuscular Levonantradol vs Oral Tetrahydrocannabinol for Patients Receiving Antineoplastic Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over								UMCC-8135


4.		Randomized Double-Blind Comparison of Metoclopramide vs Tetrahydrocannabinol to Control CACP-Induced Vomiting

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care				Closed				18 and over								MSKCC-8127


5.		Phase II Oral vs Rectal Tetrahydrocannabinol in the Treatment of CACP-Induced Nausea and Vomiting

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Closed				no age specified								NCI-D81-043-517 MDA-PC-8101


6.		Randomized Double-Blind Comparison of Tetrahydrocannabinol vs Haloperidol as Antiemetics for Cancer Patients Receiving Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Supportive care				Closed				16 and over								NCI-D79-035-229 OSU-79HO156


7.		Effect of Dosage Level on Antiemetic Properties of Tetrahydrocannabinol in Cancer Patients with Chemotherapy-Induced Nausea and Vomiting

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Supportive care				Closed				over 18								NCI-D81-014-437


8.		Antiemetic Therapy with THC for Patients Undergoing Chemotherapy for Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Supportive care				Closed				21 to 65								UMCC-7903


9.		Randomized Comparison of Droperidol vs Tetrahydrocannabinol as Anti-Emetics in Patients with Gynecologic Malignancies Treated with CACP

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Supportive care				Completed				no age specified				NCI				GOG-51

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute